18 results on '"Alizzi, S."'
Search Results
2. Tipizzazione mediante NGS e SWAB: sono compatibili?
- Author
-
Garino, E., Bertinetto, F. E., Bongioanni, D., Giordano, A., Melchiorre, T., Rocchi, L., Alizzi, S., Ferrero, N. M., Mazzola, G. A., and Amoroso, A.
- Published
- 2019
3. NGS e mutazioni nel trapianto CSE: quali informazioni agli ematologi?
- Author
-
Bertinetto, F. E., Bongioanni, D., Garino, E., Giordano, A., Melchiorre, T., Rocchi, L., Alizzi, S., Mazzola, G. A., and Amoroso, A.
- Published
- 2019
4. Tipizzazione NGS su DNA estratto da tampone buccale
- Author
-
Bertinetto, F. E., Bongioanni, D., Melchiorre, Tiziana, Rocchi, L., De Masi, A., Giordano, A., Chidichimo, Rossella, Alizzi, S., Brancatello, Francesca, Fiore, R., Navaretti, E., Garino, E., Mazzola, G. A., and Amoroso, A.
- Published
- 2017
5. Tipizzazione HLA e prove di compatibilità in urgenza: utilizzo di linfonodi o di sangue periferico?
- Author
-
Chidichimo, R., Serra, A., Alizzi, S., Boetto, M., Bongioanni, D., Brancatello, F., De Masi, A., Fiore, R., Giordano, A., Leone, E., Melchiorre, T., Navaretti, E., Oda, A., Rocchi, L., Sartorello, F., Tacconella, M., Berrino, M., Giacometti, R., Rosso, C. M., and Amoroso, A.
- Published
- 2017
6. PERCUTANEOUS RADIOFREQUENCY THERMAL ABLATION 8 RFTA) OF SMALL HEPATOCELLUALR CARCINOMA: A PROSPECTIVE STUDY
- Author
-
CAMMA', Calogero, DI MARCO, Vito, SANDONATO, Luigi, PARISI, Pietro, CABIBI, Daniela, PARDO, Salvatore, MONTALTO, Giuseppe, LATTERI, Mario, ORLANDO A, SCIARRINO E, VIRDONE R, CASARIL A, DI BONA D, ALIZZI S, NICOLI, CAMMA C, DI MARCO V, ORLANDO A, SANDONATO L, PARISI P, SCIARRINO E, VIRDONE R, CASARIL A, CABIBI D, PARDO S, DI BONA D, ALIZZI S, MONTALTO G, LATTERI MA, and NICOLI
- Abstract
PERCUTANEOUS RADIOFREQUENCY THERMAL ABLATION 8 RFTA) OF SMALL HEPATOCELLUALR CARCINOMA: A PROSPECTIVE STUDY Data: 2004 Dettaglio tipologia d'Ateneo: 3a - Articoli su riviste ISI (anche on line)
- Published
- 2004
7. The aetiological pattern of hepatocellular carcinoma ( HCC) in Italy is changing
- Author
-
DI MARCO, Vito, PARISI, Pietro, SANDONATO, Luigi, PARDO, Salvatore, CABIBI, Daniela, ALMASIO, Pier Luigi, LICATA, Anna, CAMMA', Calogero, LATTERI, Mario, CRAXI, Antonio, ALIZZI, S, ALAIMO, G, DI MARCO, V, PARISI, P, ALIZZI, S, ALAIMO, G, SANDONATO, L, PARDO, S, CABIBI, D, ALMASIO, P, LICATA, A, CAMMA', C, LATTERI, M, and CRAXI', A
- Subjects
hepatocellular carcinoma - Abstract
The aetiological pattern of hepatocellular carcinoma ( HCC) in Italy is changing.
- Published
- 2004
8. Percutaneous radiofrequency therma ablation of small hepatocellular carcinoma: a prospective study
- Author
-
CAMMA', Calogero, DI MARCO, Vito, PARISI, Pietro, PARDO, Salvatore, MONTALTO, Giuseppe, LATTERI, Mario, CRAXI, Antonio, SANDONATO L, ORLANDO A, VIRDONE R, NICOLI N, CASARIL A, CABIBBI D, ALIZZI S, DI BONA D, CAMMA C, DI MARCO V, PARISI P, SANDONATO L, ORLANDO A, VIRDONE R, NICOLI N, CASARIL A, CABIBBI D, PARDO S, ALIZZI S, DI BONA D, MONTALTO G, LATTERI MA, and CRAXI A
- Published
- 2004
9. Treatment of hepatocellular carcinoma in compensated cirrhosis with radio-frequency thermal ablation (RFTA): a prospective study
- Author
-
CAMMA, C, primary, DIMARCO, V, additional, ORLANDO, A, additional, SANDONATO, L, additional, CASARIL, A, additional, PARISI, P, additional, ALIZZI, S, additional, SCIARRINO, E, additional, VIRDONE, R, additional, and PARDO, S, additional
- Published
- 2005
- Full Text
- View/download PDF
10. 234 Percutaneous radiofrequency thermal ablation (RFTA) of small hepatocellular carcinoma: A prospective study
- Author
-
Camma, C., primary, Di Marco, V., additional, Orlando, A., additional, Sandonato, L., additional, Parisi, P., additional, Sciarrino, E., additional, Virdone, R., additional, Casaril, A., additional, Cabibi, D., additional, Pardo, S., additional, Di Bona, D., additional, Alizzi, S., additional, Montalto, G., additional, Latteri, M.A., additional, Nicoli, N., additional, and Craxi, A., additional
- Published
- 2004
- Full Text
- View/download PDF
11. Percutaneous radiofrequency thermal ablation of small hepatocellular carcinoma: A prospective study
- Author
-
Di Marco, V., Sandonato, L., Orlando, A., Parisi, P., Alizzi, S., Schepis, F., Di Bona, D., Albanese, M., Sciarrino, E., Virdone, R., Pardo, S., Sergio Salerno, Cabibi, D., Pagliaro, L., Latteri, Ma, and Craxi, A.
12. DUE FRATELLI, IL PARVOVIRUS E DUE KAWASAKI CON FENOTIPO ATIPICO
- Author
-
M. C. Maggio, A. Alaimo, R. Cimaz, C. Comparato, D. Di Lisi, C. G. Alizzi, S. Spoto, M. A. Garofalo, G. Corsello, and M.C. Maggio, A. Alaimo, R. Cimaz, C. Comparato, D. Di Lisi, C.G. Alizzi, S. Spoto, M.A. Garofalo, G. Corsello
- Subjects
Settore MED/38 - Pediatria Generale E Specialistica ,PARVOVIRUS, MALATTIA DI KAWASAKI, FENOTIPO ATIPICO - Abstract
E' rara la descrizione della Malattia di Kawasaki (MK) in fratelli, ma -se presente- è necessario escludere un trigger infettivo. Riportiamo il caso di due fratelli affetti da MK esordita contemporaneamente in seguito ad un’infezione da Parvovirus. Una bambina di 9 mesi ha presentato febbre, vomito, esantema, congiuntivite non purulenta bilaterale, linfoadenite. All’anamnesi, emergeva un episodio febbrile 12 giorni prima, con risoluzione spontanea in 5 giorni. Presentava: leucocitosi neutrofila, anemia, con transaminasi, Na, albumina, creatinina, urine nella norma. PCR: 2,31 mg/dl; VES: 120. ECG ed ecocardio sono risultati nella norma, con Z-score coronarici normali. IgM anti-Parvovirus erano positive in più determinazioni; la bimba è sfebbrata spontaneamente dopo 5 giorni. Tuttavia, è stata effettuata una rivalutazione ecocardiografica per escludere eventuale pericardite post-parvovirus che ha documentato, 26 giorni dopo la prima giornata di febbre, aneurismi coronarici multipli, anche con aspetto sacciforme, del tronco comune, delle coronarie destra e sinistra che, dopo la prima dose di IGEV (associata ad ASA a dose antiaggregante) sono ulteriormente progrediti. Pertanto, pur in apiressia e con segni di flogosi negativi, è stata trattata con 3 boli di metilprednisolone (30 mg/kg/die) in seguito ai quali non si è avuta regressione del quadro coronarico. E’ stato iniziato un farmaco biologico anti-IL1 (anakinra: 4 mg/kg7die s.c.) con progressiva regressione delle lesioni aneurismatiche e normalizzazione dello Z-score coronarico. Il fratello di 7 anni ha esordito, contemporaneamente alla sorella, con febbre, vomito, dolore addominale e spontanea risoluzione dopo 4 giorni. E’ stato ricoverato in un’altra UO per un nuovo episodio febbrile con dolore addominale, tachipnea, tachicardia, pallore, ipotensione, ritmo di galoppo, stasi alle basi polmonari, anuria secondaria a shock cardiogeno. Gli esami ematochimici evidenziavano: leucocitosi neutrofila, incremento di PCR, VES, BUN, creatinina, enzimi di necrosi miocardica (troponina-c, BNP). Le IgM anti-Parvovirus erano positive. All’ecocardiografia si evidenziava ipocinesia miocardica, severa riduzione della frazione di eiezione (20%). E’ stato trattato con dopamina, dobutamina, furosemide, prednisone, con lento e progressivo miglioramento della clinica e dei parametri ematochimici. La diagnosi iniziale del fratello è stata di miocardite post-Parvovirus. Tuttavia, alla luce del quadro della sorella, è verosimile la diagnosi di “Kawasaki shock syndrome”, pur in un quadro di MK incompleta. L’infezione da Parvovirus è trigger documentato nei due fratelli; peculiare è la contemporaneità della MK, peraltro con differente espressività. Il successo terapeutico dell’anakinra nella bambina sottolinea il ruolo della terapia con farmaco biologico anti-IL1 quale trattamento target per questo tipo di pazienti.
- Published
- 2018
13. Epidemiology and Impact of Anti-Pneumococcal Vaccination and COVID-19 on Resistance of Streptococcus pneumoniae Causing Invasive Disease in Piedmont, Italy.
- Author
-
Bondi A, Koumantakis E, Curtoni A, Barbui AM, Peradotto M, Lombardi D, Casale R, Alizzi S, Zanotto E, Charrier L, Cavallo R, and Costa C
- Abstract
Background: The international surveillance of antimicrobial resistance (AMR) reports S. pneumoniae as one of leading causes of death associated with AMR. Against invasive disease, several vaccinations are available and a reduction in AMR in S. pneumoniae has been observed. Here, we evaluated the impact of anti-pneumococcal vaccination policy and the SARS-CoV2 outbreak on AMR in S. pneumoniae causing invasive disease., Methods: We collected all strains of S. pneumoniae causing invasive disease from 2008 in the Piedmont region (Italy). Each strain was typed in order to identify the serogroup and data about AMR were collected. The population under surveillance was classified as infants, children, adults, and the old population., Results: We collected n = 2076 S. pneumoniae strains, with 21.9% and 40.3% being resistant to penicillin G and erythromycin, respectively. We reported an increased risk of infection with penicillin-resistant S. pneumoniae among all populations and evaluated whether the infection was caused by a serotype included in the vaccine formulation. A similar increase was observed after the SARS-CoV2 outbreak., Conclusions: In the Piedmont region, subsequently to the introduction of anti-pneumococcal vaccination, a significant increase in the risk of penicillin G-resistant invasive pneumococcal disease among infants and old population was reported. No significant impact was found for the SARS-CoV2 outbreak.
- Published
- 2024
- Full Text
- View/download PDF
14. Adeno-Associated Virus Type 5 Infection via PDGFRα Is Associated With Interstitial Lung Disease in Systemic Sclerosis and Generates Composite Peptides and Epitopes Recognized by the Agonistic Immunoglobulins Present in Patients With Systemic Sclerosis.
- Author
-
Moroncini G, Svegliati S, Grieco A, Cuccioloni M, Mozzicafreddo M, Paolini C, Agarbati S, Spadoni T, Amoresano A, Pinto G, Chen Q, Benfaremo D, Tonnini C, Senzacqua M, Alizzi S, Nieto K, Finke D, Viola N, Amico D, Galgani M, Gasparini S, Zuccatosta L, Menzo S, Müller M, Kleinschmidt J, Funaro A, Giordano A, La Cava A, Dorfmüller P, Amoroso A, Pucci P, Pezone A, Avvedimento EV, and Gabrielli A
- Subjects
- Humans, Receptor, Platelet-Derived Growth Factor alpha metabolism, Epitopes, Dependovirus metabolism, Autoantibodies, Molecular Docking Simulation, Peptides, Lung pathology, Scleroderma, Systemic pathology, Lung Diseases, Interstitial
- Abstract
Objective: The etiopathogenesis of systemic sclerosis (SSc) is unknown. Platelet-derived growth factor receptors (PDGFRs) are overexpressed in patients with SSc. Because PDGFRα is targeted by the adeno-associated virus type 5 (AAV5), we investigated whether AAV5 forms a complex with PDGFRα exposing epitopes that may induce the immune responses to the virus-PDGFRα complex., Methods: The binding of monomeric human PDGFRα to the AAV5 capsid was analyzed by in silico molecular docking, surface plasmon resonance (SPR), and genome editing of the PDGFRα locus. AAV5 was detected in SSc lungs by in situ hybridization, immunohistochemistry, confocal microscopy, and molecular analysis of bronchoalveolar lavage (BAL) fluid. Immune responses to AAV5 and PDGFRα were evaluated by SPR using SSc monoclonal anti-PDGFRα antibodies and immunoaffinity-purified anti-PDGFRα antibodies from sera of patients with SSc., Results: AAV5 was detected in the BAL fluid of 41 of 66 patients with SSc with interstitial lung disease (62.1%) and in 17 of 66 controls (25.75%) (P < 0.001). In SSc lungs, AAV5 localized in type II pneumocytes and in interstitial cells. A molecular complex formed of spatially contiguous epitopes of the AAV5 capsid and of PDGFRα was identified and characterized. In silico molecular docking analysis and binding to the agonistic anti-PDGFRα antibodies identified spatially contiguous epitopes derived from PDGFRα and AAV5 that interacted with SSc agonistic antibodies to PDGFRα. These peptides were also able to bind total IgG isolated from patients with SSc, not from healthy controls., Conclusion: These data link AVV5 with the immune reactivity to endogenous antigens in SSc and provide a novel element in the pathogenesis of SSc., (© 2023 The Authors. Arthritis & Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.)
- Published
- 2024
- Full Text
- View/download PDF
15. The humoral and cellular response to mRNA SARS-CoV-2 vaccine is influenced by HLA polymorphisms.
- Author
-
Bertinetto FE, Magistroni P, Mazzola GA, Costa C, Elena G, Alizzi S, Scozzari G, Migliore E, Galassi C, Ciccone G, Ricciardelli G, Scarmozzino A, Angelone L, Cassoni P, Cavallo R, Vaisitti T, Deaglio S, and Amoroso A
- Subjects
- Humans, BNT162 Vaccine, HLA-DRB1 Chains genetics, SARS-CoV-2 genetics, Alleles, COVID-19 Vaccines, COVID-19 prevention & control, COVID-19 genetics
- Abstract
Host genetic variability contributes to susceptibility to SARS-CoV-2 infection and COVID-19 evolution and the role of HLA system has not clearly emerged, suggesting the involvement of other factors. Studying response to vaccination with Spyke protein mRNA represents an ideal model to highlight whether the humoral or cellular responses are influenced by HLA. Four hundred and sixteen workers, vaccinated with Comirnaty beginning 2021, were selected within the Azienda Ospedaliera Universitaria "Città della Salute e della Scienza di Torino." The humoral response was determined with the LIAISON® kit, while the analysis of the cellular response was performed with the Quantiferon SARS-CoV-2 assay, for the S1 (receptor-binding domain; Ag1) and S1 and S2 (Ag2) subunits of the Spyke protein. Six HLA loci were typed by next-generation sequencing. Associations between HLA and vaccine response were performed with univariate and multivariate analyses. An association was found between A*03:01, B*40:02 and DPB1*06:01 and high antibody concentration and between A*24:02, B*08:01 and C*07:01 and low humoral responses. The haplotype HLA-A*01:01 ~ B1*08:01 ~ C*07:01 ~ DRB1*03:01 ~ DQB1*02:01 conferred an increased risk of low humoral response. Considering cellular responses, 50% of the vaccinated subjects responded against Ag1 and 59% against Ag2. Carriers of DRB1*15:01 displayed a higher cellular response both to Ag1 and Ag2 compared to the rest of the cohort. Similarly, DRB1*13:02 predisposed to a robust cellular response to Ag1 and Ag2, while DRB1*11:04 showed an opposite trend. Cellular and humoral responses to Comirnaty are influenced by HLA. Humoral response is mainly associated to class I alleles, with A*03:01, previously associated to protection against severe COVID-19, and response to vaccination, standing out. Cellular response predominantly involves class II alleles, with DRB1*15:01 and DPB1*13:01 prevailing. Affinity analysis for Spyke peptides is generally in line with the association results., (© 2023 The Authors. HLA: Immune Response Genetics published by John Wiley & Sons Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
16. Similarities and disparities in cancer burden among Arab world females.
- Author
-
Hussain LM, Benbrahim Z, Kunter GM, Elsayed Z, Gafer N, Hussain AM, Al-Mansouri L, Alizzi S, and Jazieh AR
- Subjects
- Female, Humans, Incidence, Middle East epidemiology, Arab World, Neoplasms epidemiology
- Abstract
Introduction: Cancer is the leading cause of increased morbidity and mortality worldwide. This work aims to study the Arab-world females' cancers (AFCs), the similarities and disparities from epidemiological, economic and development-indices points of view., Materials and Methods: Descriptive - Analytical review of the 2018 Global Cancer Observatory concerning AFCs. Data on various cancers were compiled and compared among the countries in the regions and the world females' cancers (WFCs)., Results: A total estimate of 227,494 new AFCs; 2.64% of WFCs, with an average crude incidence rate of 111.7* and an age-standardized rate of 134.5*, compared to 228* and 182.6* of WFCs, respectively. Death cases estimated to be 122,903; 2.95% of WFCs, with an average crude mortality rate of 60.3* and age-standardizedrate of 75.4*, compared to 110.2* and 83.1* of WFCs, respectively. Five-year prevalent cases were 530,735; 2.33% of WFCs, with an average proportion of 260.5*, compared to 603.5* of WFCs. Mortality to Incidence Ratio was 0.54 (range 0.36 - 0.80), compared to 0.58, 0.52, 0.49 in the medium human development index, upper-middle-income countries and world countries, respectively. */100,000 population., Conclusions: Despite the demographic and cultural similarities among the Arab communities, there are apparent disparities in AFCs. A systematic approach is required to address these remarkable differences in cancer ranking and rates among Arab countries themselves and when compared to other world groups and nations.
- Published
- 2021
17. HLA and AB0 Polymorphisms May Influence SARS-CoV-2 Infection and COVID-19 Severity.
- Author
-
Amoroso A, Magistroni P, Vespasiano F, Bella A, Bellino S, Puoti F, Alizzi S, Vaisitti T, Boros S, Grossi PA, Trapani S, Lombardini L, Pezzotti P, Deaglio S, Brusaferro S, and Cardillo M
- Subjects
- Adult, Aged, COVID-19 genetics, Female, Gene Frequency, Genetic Predisposition to Disease, Humans, Logistic Models, Male, Middle Aged, Retrospective Studies, Severity of Illness Index, ABO Blood-Group System genetics, COVID-19 etiology, HLA Antigens genetics, Polymorphism, Genetic, SARS-CoV-2
- Abstract
Background: SARS-CoV-2 infection is heterogeneous in clinical presentation and disease evolution. To investigate whether immune response to the virus can be influenced by genetic factors, we compared HLA and AB0 frequencies in organ transplant recipients and waitlisted patients according to presence or absence of SARS-CoV-2 infection., Methods: A retrospective analysis was performed on an Italian cohort composed by transplanted and waitlisted patients in a January 2002 to March 2020 time frame. Data from this cohort were merged with the Italian registry of COVID+ subjects, evaluating infection status of transplanted and waitlisted patients. A total of 56 304 cases were studied with the aim of comparing HLA and AB0 frequencies according to the presence (n = 265, COVID+) or absence (n = 56 039, COVID-) of SARS-CoV-2 infection., Results: The cumulative incidence rate of COVID-19 was 0.112% in the Italian population and 0.462% in waitlisted/transplanted patients (OR = 4.2; 95% CI, 3.7-4.7; P < 0.0001). HLA-DRB1*08 was more frequent in COVID+ (9.7% and 5.2%: OR = 1.9, 95% CI, 1.2-3.1; P = 0.003; Pc = 0.036). In COVID+ patients, HLA-DRB1*08 was correlated to mortality (6.9% in living versus 17.5% in deceased: OR = 2.9, 95% CI, 1.15-7.21; P = 0.023). Peptide binding prediction analyses showed that these DRB1*08 alleles were unable to bind any of the viral peptides with high affinity. Finally, blood group A was more frequent in COVID+ (45.5%) than COVID- patients (39.0%; OR = 1.3; 95% CI, 1.02-1.66; P = 0.03)., Conclusions: Although preliminary, these results suggest that HLA antigens may influence SARS-CoV-2 infection and clinical evolution of COVID-19 and confirm that blood group A individuals are at greater risk of infection, providing clues on the spread of the disease and indications about infection prognosis and vaccination strategies., Competing Interests: The authors have no conflicts of interest to declare., (Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
18. Rare Functional Variants in Complement Genes and Anti-FH Autoantibodies-Associated aHUS.
- Author
-
Valoti E, Alberti M, Iatropoulos P, Piras R, Mele C, Breno M, Cremaschi A, Bresin E, Donadelli R, Alizzi S, Amoroso A, Benigni A, Remuzzi G, and Noris M
- Subjects
- Atypical Hemolytic Uremic Syndrome immunology, Autoantigens immunology, Blood Proteins genetics, Child, Child, Preschool, Complement Factor H genetics, Complement Factor H immunology, Female, Genetic Predisposition to Disease, Genetic Variation, Humans, Male, Atypical Hemolytic Uremic Syndrome genetics, Autoantibodies immunology, Blood Proteins deficiency, Complement System Proteins genetics
- Abstract
Atypical hemolytic uremic syndrome (aHUS) is a rare disease characterized by microangiopathic hemolytic anemia, thrombocytopenia and renal failure. It is caused by genetic or acquired defects of the complement alternative pathway. Factor H autoantibodies (anti-FHs) have been reported in 10% of aHUS patients and are associated with the deficiency of factor H-related 1 (FHR1). However, FHR1 deficiency is not enough to cause aHUS, since it is also present in about 5% of Caucasian healthy subjects. In this study we evaluated the prevalence of genetic variants in CFH, CD46, CFI, CFB, C3 , and THBD in aHUS patients with anti-FHs, using healthy subjects with FHR1 deficiency, here defined "supercontrols," as a reference group. "Supercontrols" are more informative than general population because they share at least one risk factor (FHR1 deficiency) with aHUS patients. We analyzed anti-FHs in 305 patients and 30 were positive. The large majority were children (median age: 7.7 [IQR, 6.6-9.9] years) and 83% lacked FHR1 ( n = 25, cases) due to the homozygous CFHR3-CFHR1 deletion ( n = 20), or the compound heterozygous CFHR3-CFHR1 and CFHR1-CFHR4 deletions ( n = 4), or the heterozygous CFHR3-CFHR1 deletion combined with a frameshift mutation in CFHR1 that generates a premature stop codon ( n = 1). Of the 960 healthy adult subjects 48 had the FHR1 deficiency ("supercontrols"). Rare likely pathogenetic variants in CFH, THBD , and C3 were found in 24% of cases ( n = 6) compared to 2.1% of the "supercontrols" ( P -value = 0.005). We also found that the CFH H3 and the CD46
GGAAC haplotypes are not associated with anti-FHs aHUS, whereas these haplotypes are enriched in aHUS patients without anti-FHs, which highlights the differences in the genetic basis of the two forms of the disease. Finally, we confirm that common infections are environmental factors that contribute to the development of anti-FHs aHUS in genetically predisposed individuals, which fits with the sharp peak of incidence during scholar-age. Further studies are needed to fully elucidate the complex genetic and environmental factors underlying anti-FHs aHUS and to establish whether the combination of anti-FHs with likely pathogenetic variants or other risk factors influences disease outcome and response to therapies.- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.